Bacterial Infections  >>  Xifaxan (rifaximin)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
R+OCA, NCT03124199 / 2013-001080-23: Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection

Completed
3
40
Europe
Rifaximin
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
03/15
06/15
NCT02280044: Efficacy of Rifaximin in Preventing Campylobacteriosis

Completed
2/3
30
US
Rifaximin intervention, Placebo intervention
Johns Hopkins Bloomberg School of Public Health, Naval Medical Research Center, Uniformed Services University of the Health Sciences
Dysentery, Diarrhea, Enteric Campylobacteriosis
08/16
08/16

Download Options